Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02578095 · ClinicalTrials.gov registry record · Phase 2
Acute Hip Fracture Study in Patients 65 Years or Greater
A Phase 2 study, sponsored by Viking Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT02578095 is a Phase 2 study that has completed, run by Viking Therapeutics. The registered enrollment target is 108 participants.
The verdict
NCT02578095, a Phase 2 study, has completed, sponsored by Viking Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.
Interventions
- DRUG Placebo
- DRUG VK5211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-10-30 |
| Est. Completion | 2017-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02578095
The ClinicalTrials.gov registry entry for NCT02578095 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viking Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02578095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02578095 about?
NCT02578095 is a clinical study titled "Acute Hip Fracture Study in Patients 65 Years or Greater". This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participa...
What is the current status of trial NCT02578095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2015-10-30. Estimated completion is 2017-12-17.
What interventions are being tested in trial NCT02578095?
The interventions under investigation include: Placebo (DRUG), VK5211 (DRUG).
Who is sponsoring clinical trial NCT02578095?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.